Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
Impedimed Limited announced the issuance of 6,245,935 unquoted securities, specifically IPDAB warrants, as part of a previously disclosed transaction. This issuance, which is not intended to be quoted on the ASX, may impact the company’s financial structure and provide additional resources for its strategic initiatives, potentially influencing its market position and stakeholder interests.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices. The company’s primary products are designed for the measurement and monitoring of fluid status and body composition, which are crucial for managing conditions such as lymphedema, heart failure, and chronic kidney disease.
Average Trading Volume: 2,762,301
Technical Sentiment Signal: Hold
Current Market Cap: A$105.4M
See more insights into IPD stock on TipRanks’ Stock Analysis page.